Clinical Performance, Streptococcus Mutans Count, and Salivary pH for Cention-N, Zirconomer, and Resin-modified Glass Ionomer in Class I Restoration of Primary Molars

August 18, 2026 updated by: Galal Ali Mohamed Ebaid

Evaluation of the Clinical Performance, Streptococcus Mutans Count, and Salivary pH for Cention-N, Zirconomer, and Resin-modified Glass Ionomer in Class I Restoration of Primary Molars: A Randomized Clinical Trial

This study will evaluate the clinical performance, Streptococcus mutans count, and salivary pH for Cention-N, Zirconomer, and resin-modified glass ionomer in Class I restoration of primary molars.

Study Overview

Detailed Description

A vital aspect of overall health is dental health. Recurrent effects of oral disease on eating, sleeping, working, and social duties are subtle and widespread, and they collectively form a hidden pandemic.

The most widely used substitute for amalgam is glass ionomer cement (GIC), which has recognized the capacity to produce fluoride and played a major role in their growing application in dentistry.

The components of resin-modified GICs (RMGIC) are the same as those of ordinary glass-ionomers: polyacid, water, and basic glass powder. A monomer component and related initiator system are also present. RMGICs were created when monomeric ingredients such as 2-hydroxyethyl methacrylate (HEMA), urethane dimethacrylate (UDMA), and bisphenol-A-glycidyl methacrylate (Bis-GMA) were added to the ionomer composition.

Study Type

Interventional

Enrollment (Estimated)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Cairo, Egypt, 11651
        • Recruiting
        • Al-Azhar University (Faculty of Dentistry)
        • Sub-Investigator:
          • Adel F Hussein, MD
        • Contact:
        • Sub-Investigator:
          • Waleed O Kadour, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Children aged between 4-9 years.
  • Children who have Class I lesions in both the maxillary and mandibular arches.
  • Primary molar teeth had class I carious lesions in occlusal pits and fissures; the gap between intercuspal surfaces should not be exceeded during cavity preparation.
  • Primary molars free of periapical pathosis.
  • Primary molars free root resorption.

Exclusion Criteria:

  • Primary molars with preapical pathosis or hypersensitivity.
  • Primary molars with periodontal diseases or mobile molar tooth that indicated for extraction.
  • Nonfunctioning teeth with no opposing dentition; heavy occlusion or signs of severe attrition; and endodontically treated teeth.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A
Primary molars with Class I cavity restoration using Cention-N material according to the manufacturer's instructions.
Class I cavity restoration using Cention-N self-curing resin-based dental restorative material according to the manufacturer's instructions.
Experimental: Group B
Primary molars with Class I cavity restoration using Zirconomer material according to the manufacturer's instructions
Class I cavity restoration using Zirconomer zirconia-reinforced glass ionomer restorative material according to the
Active Comparator: Group C
Primary molars with Class I cavity restoration using Resin-Modified Glass Ionomer (RMGI) material according to the manufacturer's instructions
Class I cavity restoration using Resin-Modified Glass Ionomer (RMGI) restorative material according to the manufacturer's instructions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Performance of Restorations
Time Frame: 6 months post-restoration
Evaluation of the clinical performance of restorations using modified USPHS (FDI) criteria. It systematically grades how restorative materials (like composite resins, glass ionomers, and ceramics) perform in the mouth over time
6 months post-restoration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Streptococcus Mutans Count
Time Frame: 6 months post-restoration
Assessment of Streptococcus mutans bacterial count in saliva/plaque samples expressed in CFU/mL will be recorded.
6 months post-restoration
Salivary pH Level
Time Frame: 6 months post-restoration
Salivary pH changes will be measured using a digital pH meter.
6 months post-restoration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2025

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

August 18, 2026

First Submitted That Met QC Criteria

August 18, 2026

First Posted (Actual)

August 20, 2026

Study Record Updates

Last Update Posted (Actual)

August 20, 2026

Last Update Submitted That Met QC Criteria

August 18, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 1021/3954

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

IPD Sharing Time Frame

After the end of study for one year.

IPD Sharing Access Criteria

The data will be available upon a reasonable request from the corresponding author.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe